Y-Prime, Inc., announces today that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with Non-Small Cell Lung Carcinoma (NSCLC). This study will be conducted utilizing their proprietary eClinical Supply Forecasting tool (eCSF), along with their state-of-the-art Interactive Response Technology (IRT).
Throughout this trial, YPrime will be supporting world class selected sites to conduct the study with data driven metrics pulled from these tools. YPrime is dedicated to applying its leading edge eClinical technology to help forward unmet medical needs in the Biotech and Pharmaceutical industry.
“Our team is very pleased to continue helping Biotech and Pharmaceutical companies track patient activity and ensure the clinical supply chain runs smoothly with international studies. We have added significant value by playing a critical role in the successful integration of eClinical solutions for this virtual Biopharma organization.” said Shawn Blackburn, President and Co-founder of YPrime.